Evolent Health Inc (NYSE:EVH) CFO Nicholas Mcgrane sold 1,667 shares of Evolent Health stock in a transaction dated Wednesday, April 19th. The stock was sold at an average price of $22.52, for a total value of $37,540.84. Following the sale, the chief financial officer now owns 132,047 shares of the company’s stock, valued at approximately $2,973,698.44. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Nicholas Mcgrane also recently made the following trade(s):

  • On Friday, March 24th, Nicholas Mcgrane sold 7,034 shares of Evolent Health stock. The stock was sold at an average price of $22.50, for a total value of $158,265.00.

Shares of Evolent Health Inc (NYSE:EVH) traded down 0.22% during mid-day trading on Friday, reaching $22.30. The company’s stock had a trading volume of 571,667 shares. The firm’s 50 day moving average is $21.23 and its 200-day moving average is $19.67. The company’s market capitalization is $1.17 billion. Evolent Health Inc has a 52-week low of $10.40 and a 52-week high of $26.84.

Evolent Health (NYSE:EVH) last issued its earnings results on Tuesday, February 28th. The technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.15. Evolent Health had a negative return on equity of 5.54% and a negative net margin of 69.04%. The firm earned $88 million during the quarter, compared to analyst estimates of $84.98 million. During the same period in the previous year, the company earned ($0.05) earnings per share. The business’s revenue for the quarter was up 90.9% on a year-over-year basis. Analysts forecast that Evolent Health Inc will post ($0.41) EPS for the current year.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/04/21/evolent-health-inc-evh-cfo-nicholas-mcgrane-sells-1667-shares.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can raised its position in shares of Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock valued at $138,000 after buying an additional 6,077 shares during the last quarter. Pacad Investment Ltd. purchased a new position in shares of Evolent Health during the fourth quarter valued at $165,000. Bayesian Capital Management LP purchased a new position in shares of Evolent Health during the fourth quarter valued at $234,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Evolent Health during the fourth quarter valued at $332,000. Finally, Trexquant Investment LP purchased a new position in shares of Evolent Health during the fourth quarter valued at $350,000. 52.14% of the stock is currently owned by institutional investors.

A number of analysts recently commented on the company. Jefferies Group LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a research report on Thursday, April 13th. CIBC assumed coverage on Evolent Health in a research report on Tuesday, March 14th. They set an “outperform” rating for the company. Oppenheimer Holdings Inc. assumed coverage on Evolent Health in a research report on Monday, March 13th. They set an “outperform” rating and a $28.00 price objective for the company. Goldman Sachs Group Inc upgraded Evolent Health from a “buy” rating to a “conviction-buy” rating and set a $30.00 price objective for the company in a research report on Wednesday, March 8th. Finally, Zacks Investment Research upgraded Evolent Health from a “strong sell” rating to a “hold” rating in a research report on Friday, March 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $27.22.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

5 Day Chart for NYSE:EVH

Receive News & Stock Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related stocks with our FREE daily email newsletter.